Biotechnology
News Category

Quantum BioPharma Gets FDA Green Light for Phase 2 Trial of Lucid-MS in Multiple Sclerosis
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential neuroprotective therapy for mult...

PX1 Research Expands cGMP-Compliant Manufacturing with 99%+ HPLC Purity Verification for Research Peptides
PX1 Research's adoption of seven-stage HPLC purity testing and cGMP standards in US-based manufacturing ensures batch-specific documentation, addressi...

NanoViricides Gets Regulatory Nod for Phase II Ebola Trial of NV-387 Oral Gummies in DRC
NanoViricides has received approval to start a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessibl...

Telomir Pharmaceuticals Publishes Peer-Reviewed Data Supporting Telomir-Zn as Potential TNBC Therapy
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in triple-negative breast cancer models, s...

Quantum BioPharma Receives FDA Clearance to Advance Lucid-MS into Phase 2 for Multiple Sclerosis
Quantum BioPharma's FDA clearance for Lucid-MS to enter Phase 2 trials marks a pivotal step in developing a neuroprotective therapy for multiple scler...

Tonix Pharmaceuticals Reports Strong Q2 Sales for TONMYA, Advancing Pipeline Programs
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA sales, demonstrating commercial viability and supporting pipeline pro...

Tonix Pharmaceuticals Reports Q2 Revenue Surge as TONMYA Sales Reach $11 Million, Signaling Strong Market Uptake
Tonix Pharmaceuticals' second-quarter revenue jumped to $13.5 million driven by TONMYA's strong launch, positioning the company for sustained growth i...

Regentis Biomaterials Advances GelrinC Toward Regulatory Approval and Commercial Expansion
Regentis Biomaterials is progressing its GelrinC cartilage regeneration implant through clinical trials, FDA submission preparation, and European comm...

Quantum BioPharma's Dual Strategy Targets Neurological Health with Lucid-MS and unbuzzd
Quantum BioPharma advances a two-pronged approach to neurological health, combining its investigational MS therapy Lucid-MS with its supplement unbuzz...

Quantum BioPharma Advances Dual Strategy for Neurological Health with MS Therapy and Alcohol Supplement
Quantum BioPharma is advancing a two-pronged approach to neurological health, targeting myelin repair in multiple sclerosis with Lucid-MS and addressi...

VERAXA Biotech Builds Strategic Position in Antibody Therapeutics Market
VERAXA Biotech's proprietary BiTAC platform and pipeline of next-generation antibody therapeutics position it for potential partnerships and licensing...

Spanish Patient Case Highlights Risks of Poorly Cooked Pork and Diagnostic Challenges
A Spanish patient initially treated for brain cancer was found to have pork tapeworm cysts, underscoring the importance of proper pork preparation and...

VERAXA Advances VXA-222 Cancer Program and Expands Patent Portfolio
VERAXA Biotech has advanced its VXA-222 bispecific ADC program past the discovery phase and expanded its patent portfolio, underscoring its progress i...

New Liquid Biopsy Predicts Immunotherapy Response in Advanced Lung Cancer
A novel liquid biopsy offers a simpler method to predict which advanced lung cancer patients will respond to immunotherapy, potentially improving trea...

GeoVax Completes Key GEO-MVA Milestones, Paving Way for Pivotal Phase 3 Study
GeoVax announces completion of manufacturing, regulatory, clinical, and preclinical milestones for its GEO-MVA mpox/smallpox vaccine, positioning it f...

Onco-Innovations Integrates Targeted Cancer Therapy, Nanotechnology, and AI to Advance Oncology Drug Development
Onco-Innovations is combining PNKP-targeted DDR inhibition, nanoparticle delivery, and causal AI to accelerate cancer drug development, with lead cand...

Ancient Immune Protein C3 Found to Enhance Immunotherapy Effectiveness Against Tumors
Nagoya University researchers discovered that the immune protein C3, when produced within tumors, can make them more susceptible to immunotherapy, pot...

VolitionRx Publishes Peer-Reviewed Study on Capture-Seq Liquid Biopsy Technology
VolitionRx's new Capture-Seq technology achieves >99% pure ctDNA isolation, potentially transforming cancer detection and monitoring, with a combined ...

Tonix Pharmaceuticals to Present at Major Investor Conferences in August and September
Tonix Pharmaceuticals announced its participation in two key investor conferences, highlighting its ongoing efforts to engage with the investment comm...

VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, strength...

NeuroThera Labs Expands Phase IIb Trial of SCI-110 for Tourette Syndrome to Yale Child Study Center
NeuroThera Labs has initiated its Phase IIb clinical trial at Yale Child Study Center, advancing a potential new cannabinoid-based treatment for Toure...

SRX Global Acquires Stake in Vistagen Therapeutics, Signaling Confidence in Neuroscience Pipeline
SRX Global's investment in Vistagen Therapeutics underscores its strategy to unlock value in undervalued biopharmaceutical assets, potentially influen...

SRX Global Acquires Stake in Vistagen Therapeutics, Seeing Undervaluation
SRX Global's acquisition of a stake in Vistagen highlights its strategy of investing in undervalued high-conviction companies and engaging with manage...

Quantum BioPharma's MS Imaging Study Shows Encouraging Preliminary Results at Enrollment Midpoint
Quantum BioPharma's pilot MS imaging study with Massachusetts General Hospital has reached its enrollment midpoint with promising preliminary data, po...

Biotech Labz Supply Expands Catalog with 11 Documented Research Peptides
Biotech Labz Supply Inc now offers 11 high-purity research peptides, including BPC-157 and Tesamorelin, all backed by batch-specific certificate of an...

Oncotelic Therapeutics to Present at OTCQB Virtual Investor Conference, Highlighting Key Clinical and Platform Advancements
Oncotelic Therapeutics is set to present at the OTCQB Virtual Investor Conference, showcasing progress in its Phase 1b trial, platform validation, and...

Tonix Pharmaceuticals Receives FDA Feedback Supporting Phase 2 Study of Lyme Disease Prevention Candidate
Tonix Pharmaceuticals announced FDA feedback supporting its adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Lyme disea...

Independent Research Supports Broader Filovirus Vaccine Strategies, Highlighting Value of GeoVax's MVA Platform
Recent independent findings suggest cross-reactive immune responses among ebolaviruses, reinforcing the strategic importance of GeoVax's multi-antigen...

Regentis Biomaterials Advances GelrinC, a First-in-Class Off-the-Shelf Cartilage Regeneration Platform
Regentis Biomaterials is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, addressing a major unmet need...

Quantum BioPharma Reaches Halfway Point in MS Imaging Study with Encouraging Preliminary Data
Quantum BioPharma's pilot MS imaging study with Massachusetts General Hospital shows promising early results, potentially enhancing the development of...

NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum Classical Workflow for Clinical Data Analytics
NeuroThera Labs announced its quantum platform successfully processed real-world clinical data through a full hybrid quantum-classical analytical work...

NeuroOne White Paper Details StereoCED Platform Designed to Overcome Barriers in CNS Drug Delivery
NeuroOne released a white paper on its StereoCED platform, which aims to address scalability challenges in brain drug delivery by enabling simultaneou...

VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC® Cancer Therapy Platform
VERAXA Biotech strengthens scientific leadership with a new CSO as it advances its proprietary BiTAC® platform toward clinical development, positionin...

Onco-Innovations Closes CAD$5 Million Private Placement to Advance Oncology Programs
Onco-Innovations Limited closed a CAD$5 million private placement with Sorbie Bornholm LP and Sorbie Investments LLP, providing funding to advance its...

Lexaria Bioscience Implements 1-for-15 Reverse Stock Split to Regain Nasdaq Compliance
Lexaria Bioscience Corp. announces a 1-for-15 reverse stock split effective August 3, 2026, to increase its share price above the Nasdaq minimum $1.00...

VolitionRx Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test for Sepsis and Other Diseases
VolitionRx Limited announces that multiple peer-reviewed studies confirm its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, c...

Instinct Bio Partners with INVITRX to Bring GENREVER to U.S. and Boost Indonesia's Regenerative Medicine
Instinct Bio announces a strategic collaboration with INVITRX to expand its GENREVER cosmetic line into the U.S. and support regenerative medicine ini...

Renaissance BioScience Appoints Dr. James Tansey to Board of Directors
Renaissance BioScience Corp. appoints Dr. James Tansey, a seasoned entrepreneur and academic, to its board to support growth and commercialization of ...

BRAIN Biotech AG Appoints Dr. Sven K. Weber as CEO, Succeeding Adriaan Moelker
Dr. Sven K. Weber, former BASF Vice President, will become CEO of BRAIN Biotech AG on October 1, 2026, as Adriaan Moelker retires after six years of r...

VERAXA Biotech Expands Patent Portfolio for Next-Generation Cancer Therapies
VERAXA Biotech has expanded its patent portfolio with new filings covering its BiTAC-TCE and BiTAC-ADC platforms, strengthening protection through 204...

MindBio Therapeutics Delivers First Edge AI Kiosk Prototypes for Rapid Impairment Screening
MindBio Therapeutics has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, aiming to provide rapid, scala...

VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC(R) Cancer Therapy Platform
VERAXA Biotech strengthens its scientific leadership with the appointment of Dr. Christoph Erkel as Chief Scientific Officer, positioning the company ...

VERAXA Biotech Expands Patent Portfolio to Protect Next-Generation Cancer Therapy Platforms
VERAXA Biotech AG announced the expansion of its intellectual property portfolio with new patent applications covering its BiTAC-TCE and BiTAC-ADC pla...

Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology
Greenland Mines (GRML) obtained a Canadian patent for Klotho-based gene therapies targeting neurodegenerative diseases, expanding its IP portfolio and...

Quantum BioPharma Advances Lucid-MS and Commercial Growth in Podcast Interview
Quantum BioPharma's executive outlines the development strategy for Lucid-MS, a potential multiple sclerosis treatment, and highlights the commercial ...

VERAXA Biotech Shareholders Overwhelmingly Approve Governance and Financing Proposals
VERAXA Biotech shareholders approved corporate governance and financing measures with over 99.94% support, enabling greater flexibility for acquisitio...

Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology Targeting Neurodegenerative Diseases
Greenland Mines Ltd. has been granted a Canadian patent for Klotho-based gene therapies, expanding its IP portfolio and advancing treatments for Alzhe...
